Myosteatosis independently predicts transplant-free survival in patients with primary sclerosing cholangitis

Dig Liver Dis. 2023 Nov;55(11):1543-1547. doi: 10.1016/j.dld.2023.08.037. Epub 2023 Aug 14.

Abstract

Background: Primary Sclerosing Cholangitis (PSC) is a progressive cholestatic liver disease with liver transplantation (LT) as the only curative therapy. Some regions use body-weight-loss as standard-exception criteria for organ allocation but data on the impact of body composition on survival of patients with PSC is scarce.

Methods: Abdominal MRI of PSC patients were quantitatively analyzed for intramuscular fat fraction (IMFF) as surrogate of myosteatosis. Clinical and laboratory data were retrieved from patient records. Primary outcome was transplant-free survival (TFS).

Results: 116 PSC patients were included. Median age was 38 (18-71) years with 74 (64%) male patients. 15 (13%) patients had significant weigh loss. IMFF was significantly associated with survival. Multivariate regression analysis showed IMFF ≥ 15% as independent predictor for TFS (p = 0.032, HR 3.215 CI 1.104-9.366), but not significant weight loss (p = 0.618).

Conclusion: IMFF is independently associated with TFS in patients with PSC and may identify patients with more urgent need for LT. NCT03584204.

Keywords: Intramuscular fat fraction; Liver transplantation; Myosteatosis; PSC; Primary sclerosing cholangitis; Sarcopenia.

Publication types

  • Clinical Study

MeSH terms

  • Adult
  • Cholangitis, Sclerosing* / complications
  • Cholangitis, Sclerosing* / surgery
  • Female
  • Humans
  • Liver Transplantation*
  • Male

Associated data

  • ClinicalTrials.gov/NCT03584204